Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC

October 30, 2017 – Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non–small cell lung cancer (NSCLC). A Merck spokesperson told OncLive that the company withdrew the application “based on discussions with the European regulatory authorities,” but did not give any further explanation. The company reported in a press release … (leggi tutto)